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Summary
Background Parenteral antibiotic therapy for young infants (aged 0–59 days) with suspected sepsis is sometimes not 
available or feasible in countries with high neonatal mortality. Outpatient treatment could save lives in such settings. 
We aimed to assess the equivalence of two simpliﬁ ed antibiotic regimens, comprising fewer injections and oral rather 
than parenteral administration, compared with a reference treatment for young infants with clinical severe infection.
Methods We undertook the Simpliﬁ ed Antibiotic Therapy Trial (SATT), a three-arm, randomised, open-label, 
equivalence trial in ﬁ ve communities in Karachi, Pakistan. We enrolled young infants (aged 0–59 days) who either 
presented at a primary health-care clinic or were identiﬁ ed by a community health worker with signs of clinical severe 
infection. We included infants who were not critically ill and whose family refused admission. We randomly assigned 
infants to either intramuscular procaine benzylpenicillin and gentamicin once a day for 7 days (reference); oral 
amoxicillin twice daily and intramuscular gentamicin once a day for 7 days; or intramuscular procaine benzylpenicillin 
and gentamicin once a day for 2 days followed by oral amoxicillin twice daily for 5 days. The primary outcome was 
treatment failure within 7 days of enrolment and the primary analysis was per protocol. We judged experimental 
treatments as eﬃ  cacious as the reference if the upper bound of the 95% CI for the diﬀ erence in treatment failure was 
less than 5·0. This trial is registered at ClinicalTrials.gov, number NCT01027429.
Findings Between Jan 1, 2010, and Dec 26, 2013, 2780 infants were deemed eligible for the trial, of whom 2453 (88%) 
were enrolled. Because of inadequate clinical follow-up or treatment adherence, 2251 infants were included in the 
per-protocol analysis. 820 infants (747 per protocol) were assigned the reference treatment of procaine benzylpenicillin 
and gentamicin, 816 (751 per protocol) were allocated amoxicillin and gentamicin, and 817 (753 per protocol) were 
assigned procaine benzylpenicillin, gentamicin, and amoxicillin. Treatment failure within 7 days of enrolment was 
reported in 90 (12%) infants who received procaine benzylpenicillin and gentamicin (reference), 76 (10%) of those given 
amoxicillin and gentamicin (risk diﬀ erence with reference –1·9, 95% CI –5·1 to 1·3), and 99 (13%) of those treated with 
procaine benzylpenicillin, gentamicin, and amoxicillin (risk diﬀ erence with reference 1·1, –2·3 to 4·5).
Interpretation Two simpliﬁ ed antibiotic regimens requiring fewer injections are equivalent to a reference treatment 
for young infants with signs of clinical severe infection but without signs of critical illness. The use of these simpliﬁ ed 
regimens has the potential to increase access to treatment for sick young infants who cannot be referred to hospital.
Funding The Saving Newborn Lives initiative of Save the Children, through support from the Bill & Melinda Gates, 
and by WHO and USAID. 
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Despite improvements in child survival over recent 
decades, progress in newborn survival remains slow, with 
44% of all child deaths occurring in the ﬁ rst month of life. 
Of these neonatal deaths, 23–30% are due to infections.1
WHO recommends hospital referral and 7 days of 
injectable penicillin and gentamicin for neonates and 
young infants (aged 0–59 days) with suspected sepsis.2 
However, up to three-quarters of families of sick young 
infants in Karachi, Pakistan, refuse hospital referrals, 
despite free transport and treatment, because of the 
substantial opportunity costs to very poor families of 
prolonged admissions at locations far from their place 
of residence.3 Stated reasons for refusal are ﬁ nancial 
constraints, cultural beliefs, and concern about poor quality 
of care at hospitals.3,4 Similar constraints to optimum care 
of sick newborn babies in high-mortality settings have also 
been noted from other low-resource settings.5
An expert consultation reviewed the issue of low 
adherence to referral advice for sick young infants and 
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recommended that clinical trials were needed to evaluate 
simpliﬁ ed antibiotic regimens to manage severe 
infections in young infants when referral was not 
possible, to improve access to care and newborn survival.6 
Thus, randomised controlled trials assessing simpliﬁ ed 
antibiotic regimens—ie, fewer injections, addition of 
high-dose oral amoxicillin in lieu of penicillin—for 
outpatient management of young infants with clinical 
severe infection were undertaken in several countries 
(Democratic Republic of Congo, Bangladesh, Kenya, 
Nigeria, and Pakistan) to ensure wide generalisability.7–10 
These trials were not designed to show that the simpler 
regimens were better than the standard regimen but 
rather that they had similar eﬃ  cacy to the reference 
regimen—namely, an equivalence or non-inferiority 
design.11 Thus, the trials were designed to produce narrow 
conﬁ dence intervals when examining the diﬀ erence in 
risk of treatment failure between the simpliﬁ ed regimens 
and the reference treatment and, hence, provide a high 
degree of conﬁ dence that any diﬀ erences between eﬃ  cacy 
of the treatments were small. The choice of treatment 
regimens followed a systematic review of pathogens 
causing neonatal sepsis,12 their antimicrobial resistance 
patterns,13 antibiotic pharmacodynamics in neonates,14 
and existing evidence on treatment success with various 
oral and injectable antibiotics in young infants.15,16
We targeted young infants (aged 0–59 days) with 
clinical severe infections because increased susceptibility 
to infection persists into the second month of life.17 
Additionally, the signs and management of sepsis in 
young infants (aged 29–59 days) are similar to those in 
neonates (aged 0–28 days). WHO and UNICEF’s 
Integrated Management of Childhood Illness (IMCI) 
strategy addresses children aged 0–59 days as a separate 
group (young infants) from children aged 2–59 months.18
Here, we present data from the Simpliﬁ ed Antibiotic 
Therapy Trial (SATT) undertaken in Karachi, Pakistan,8 
to compare the risk of treatment failure in young infants 
with a diagnosis of clinical severe infection between 
a reference treatment and two simpliﬁ ed antibiotic 
regimens, comprising fewer injections and a high dose 
of an oral antibiotic in lieu of parenteral administration.
Methods
Study design and participants
SATT Pakistan is a randomised open-label trial designed 
to assess equivalence of three outpatient-based antibiotic 
regimens. We undertook the trial in ﬁ ve low-income 
settlements in coastal Karachi, Pakistan (Rehri Goth, 
Ibrahim Hyderi, Ali Akbar Shah Goth, Bhains colony, 
and Bilal colony), which are roughly 1 h drive from the 
main campus of the Aga Khan University in Karachi. 
These settlements are served by ﬁ ve primary health-
care clinics, have an annual birth cohort of 8000, and 
have ongoing household surveillance of young infants 
aged 0–59 days (appendix p 1).
Infants from the catchment area were either referred to 
a study clinic by community health workers during 
routine household surveillance or presented with their 
family at one of the ﬁ ve primary health-care clinics, at 
which study clinicians screened them for eligibility 
to participate in the trial.8 Inclusion criteria were 
age 0–59 days, living in the catchment area, refusal by 
family to be admitted to hospital, and one or more signs 
of clinical severe infection (panel). Infants were excluded 
from the study if their family agreed to admission, weight 
at presentation was less than 1500 g, major congenital 
malformations or suspected chromosomal abnormalities 
were present, surgical conditions needed hospital 
referral, they had been admitted for illness in the past 
2 weeks, they had been included previously in the study, 
or they had one or more signs of critical illness (panel). 
If the infant had signs of clinical severe infection, the 
study clinician ﬁ rst recommended hospital referral. 
Research in context
Evidence before the study
We searched PubMed between January, 1990, and 
October, 2015, with the terms “young infant”, “clinical severe 
infection”, and “simpliﬁ ed antibiotic regimens” to identify 
peer-reviewed publications in the English language about 
simpliﬁ ed antibiotic regimens for severe infections in neonates 
and young infants in the primary-care setting. We identiﬁ ed 
ﬁ ve reports (three protocol papers), of which two reported 
ﬁ ndings of similar trials undertaken in Africa (Kenya, Nigeria, 
and Democratic Republic of Congo) and Bangladesh, comparing 
the WHO-recommended regimen of parenteral penicillin and 
gentamicin with simpler antibiotic regimens.
Added value of this study
Compared with previous studies in Africa and Bangladesh, our 
trial from Pakistan had a higher representation of very young 
infants (those in the ﬁ rst week of life) and was enriched by the 
availability of bacterial aetiological data and antimicrobial 
susceptibility data. A pooled analysis can now be done of data 
from all three related trials, to support policy recommendations 
for this very young group of patients.
Implications of all the available evidence
The ﬁ ndings of our trial are consistent with those published 
previously, showing that simpliﬁ ed antibiotic regimens are as 
eﬃ  cacious as the WHO-recommended regimen of parenteral 
penicillin and gentamicin for young infants with severe 
infection. Our study has contributed to development of new 
WHO guidelines for treatment of severe infection in young 
infants where referral is not feasible. 
See Online for appendix
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If the family refused admission and the infant had no 
signs of critical illness, the study clinician oﬀ ered trial 
enrolment with facility-based and home-based treatment. 
If the infant had signs of critical illness, parents were 
counselled again on the importance of hospital referral. 
If parents still refused admission, they were oﬀ ered the 
reference treatment (ie, procaine benzylpenicillin and 
gentamicin) and were not enrolled or randomly allocated. 
Study methods have been described in detail.8
We obtained written informed consent for infants to 
participate in the trial from parents or guardians. Consent 
included documentation of the refusal for hospital 
referral and acceptance of enrolment. A third party 
(community member) witnessed the consent procedure, 
and this individual also signed the consent form. We read 
the consent form to illiterate participants and took a 
thumbprint in lieu of a signature, which a third party 
witness countersigned. The study was approved by the 
ethics review committee of the Aga Khan University, 
ethics review committee of WHO, and the ethics 
committee at the London School of Hygiene & Tropical 
Medicine.
Randomisation and masking
After obtaining consent, we randomly allocated infants to 
one of three antibiotic regimens: 7 days of procaine 
benzylpenicillin and gentamicin, administered intra mus-
c ularly (reference treatment); intramuscular gentamicin 
once a day and oral amoxicillin twice daily for 7 days; or 
procaine benzylpenicillin and gentamicin administered 
intramuscularly once a day for 2 days followed by oral 
amoxicillin twice daily for 5 days. We used a site-speciﬁ c 
and age-speciﬁ c (<7 days and 7–59 days) randomisation 
sequence list generated by the London School of Hygiene 
& Tropical Medicine.8 The allocation sequence for every 
site and age group was placed in serially numbered, 
sealed, opaque envelopes by the Data Management Unit 
at Aga Khan University and delivered to every site. Study 
clinicians selected the next envelope and the treatment 
corresponding to the allocation code printed within was 
assigned to the infant. Study participants’ families and 
study clinicians were not blinded to treatment allocation 
because giving placebo injections to sick young infants 
was judged unethical.
Procedures
Study drugs were provided by the Aga Khan University 
pharmacy, stored at room temperature away from direct 
sunlight at study clinics, and administered using study-
speciﬁ c dosage charts present at every public health-care 
clinic (appendix p 2). We administered intramuscular 
procaine benzylpenicillin (40 000–60 000 units per kg) 
once a day, intramuscular gentamicin (4·0–5·0 mg/kg in 
early neonates aged 0–6 days; 5·0–6·5 mg/kg in infants 
aged 7–59 days) once a day, and oral amoxicillin 
(75–100 mg/kg per day) twice daily in divided doses. 
Paramedics or study clinicians administered intra-
muscular injections at study clinics; study personnel gave 
the morning dose of oral amoxicillin at the clinic, and a 
community health worker visiting the child’s household 
administered the evening dose. If the baby vomited within 
30 min, the oral drug was re-administered. We followed 
up every participant daily at the public health-care clinics, 
from enrolment to day 8, then on day 11 and day 14 for 
vital signs (respiratory rate, temperature, and heart rate), 
danger signs of critical illness (panel), improvement or 
deterioration in clinical status (deﬁ ned as resolution or 
presence of one danger sign of critical illness),8 and 
adverse events (ie, relapse, death, or treatment failure). We 
referred young infants who failed treatment to hospital. If 
families still refused admission, we treated the infant with 
intramuscular ceftriaxone once a day for 1 week.
We collected blood samples at enrolment using 
appropriate aseptic precautions. We captured blood sample 
collection procedures on video for about 10% of participants 
as a quality assurance measure. We injected about 2–3 mL 
of blood (median 2·1 mL [IQR 1·4–2·8]) into a bottle 
(BACTEC Peds Plus; Becton Dickinson, Franklin Lakes, 
NJ, USA) and transported the sample to the Infectious 
Disease Research Laboratory at Aga Khan University 
within 3 h of collection; we incubated the sample in a 
continuous monitoring system (BACTEC 9240; Becton 
Dickinson) for 5 days. If bottles were ﬂ agged positive by 
the automated system, we Gram-stained and subcultured 
blood culture broth on appropriate media—eg, 5% sheep 
blood agar and chocolate agars incubated in 5% CO2 at 
Panel: Case deﬁ nitions
Clinical severe infection
Signs of clinical severe infection were deﬁ ned as:
• Movement only when stimulated
• Not feeding well on observation
• Temperature ≥38°C or <35·5°C
• Severe chest indrawing (inward chest movement with 
every breath in 1 min)
Critical illness
Signs of critical illness were deﬁ ned as:
• Unconsciousness
• Convulsions
• Inability to feed
• Apnoea
• Inability to cry
• Cyanosis
• Bulging fontanelle
• Major congenital malformations inhibiting oral antibiotic 
intake
• Active bleeding needing transfusion
• Surgical conditions needing hospital referral
• Persistent vomiting (ie, vomiting after three attempts to 
feed the infant within 30 min, with the infant vomiting 
after each attempt) 
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35°C; Maconkey agar incubated in air at 35°C; or 5% sheep 
blood agar incubated anaerobically at 35°C. We did all 
identiﬁ cation and susceptibility tests in accordance with 
American Society for Microbiology procedures and Clinical 
Laboratory Standards Institute guidelines,19 when 
applicable. For a few blood cultures that were smear-
positive for campylobacter-like organisms but that did not 
yield bacterial growth on conventional culture, we also did 
PCR of the 23S RNA-conserved region of campylobacter, 
helicobacter, and arcobacter complex. Brieﬂ y, we extracted 
DNA (MagNA Pure extraction kit; Roche Diagnostics, 
Burgess Hill, UK) then did conventional PCR (Eppendorf 
MasterCycler Gradient; Marshall Scientiﬁ c, Hampton, 
NH, USA)20 and gel electrophoresis.
We categorised blood culture results as no growth, 
contamination, or bacteraemia (known or probable 
pathogen). We classed blood cultures with growth of 
common skin ﬂ ora as contamination. We used 
bacteraemia to describe blood cultures positive for 
known pathogens, whether isolated singly or mixed with 
other pathogens or contaminants, or pathogens less 
commonly associated with neonatal sepsis, whether 
isolated singly or mixed with other pathogens or 
contaminants (appendix p 3).
We checked for adverse events at every follow-up visit. 
Community health workers reported adverse events to 
study doctors at every study clinic, who graded them as 
serious or non-serious. Serious adverse events were 
those possibly related to study drugs, including: severe 
diarrhoea with dehydration requiring facility manage-
ment; Stevens-Johnson syndrome; anaphylaxis; and 
acute renal failure. A study supervisor (trained 
paediatrician) veriﬁ ed the grading. Quarterly adverse 
event reports were reviewed by the study’s data safety 
and monitoring board and technical scientiﬁ c committee.
Outcomes
The primary outcome of our trial was treatment failure 
within 7 days of enrolment, which we deﬁ ned as either: 
death; admission; clinical deterioration;8 change in 
antibiotic regimen because of infectious comorbidity (to 
intramuscular ceftriaxone); serious adverse event; 
occurrence of a new sign of clinical severe infection 
(panel) on or after day 3; persistence of presenting signs 
at day 4; or recurrence of initial signs of sepsis on or after 
day 5. Among young infants who had treatment failure, 
secondary outcomes were: death within 7 days of 
enrolment; death at any time before the day 14–15 
assessment; and admission for any reason at any time 
within 7 days of enrolment. Among children who did not 
have treatment failure, secondary outcomes were: 
admission at any time between the day 8 and day 14–15 
visits; death at any time between the day 8 and 
day 14–15 visits; and non-fatal relapse at any time 
between the day 8 and day 14–15 visits (deﬁ ned as 
admission, development of any sign of critical illness, or 
development of any sign of suspected sepsis).
Statistical analysis
We postulated (from our previous experience) that the 
simpliﬁ ed antibiotic regimens would have equivalent 
eﬃ  cacy to the reference treatment and that the risk of 
treatment failure would be 10% in all groups. For every 
comparison with the reference treatment, we planned to 
estimate the diﬀ erence in the risk of failure between the 
two treatment groups and to use a two-sided 95% CI to 
assess the equivalence of the two simpliﬁ ed antibiotic 
regimens. We judged simpliﬁ ed antibiotic regimens as 
eﬃ  cacious as the reference if the upper bound of the 
95% CI for the diﬀ erence in treatment failure was less 
than 5. Based on this criterion, we estimated that a 
sample size of 750 assessable children per treatment 
group would provide at least 90% power to show that the 
simpliﬁ ed antibiotic regimens were as eﬃ  cacious as the 
reference treatment.
Since the aim of our trial was to show the equivalence of 
diﬀ erent antibiotic regimens, rather than superiority of 
one regimen over another, we analysed the primary 
outcome per protocol8 rather than by intention to treat, 
which would tend to reduce any diﬀ erences between 
treatment regimens. We deﬁ ned per-protocol infants as 
those who had completed clinical follow-up fully 
(eight visits on 8 days) or partly (three visits days 2–4, at 
least one visit days 5–8, and known vital status at day 8) 
and who had adhered to treatment fully or partly (appendix 
p 6). We deﬁ ned infants who were fully adherent to 
treatment as those who received all doses of scheduled 
antibiotics for 7 days (or by the time of treatment failure, if 
failure occurred) and who had not received any other 
antibiotic from a study or non-study clinician. We deﬁ ned 
infants who were partly adherent to treatment as those 
who had received all scheduled antibiotics on the ﬁ rst 
3 days of treatment (or by the time of treatment failure) 
and at least 50% of all scheduled doses of each antibiotic 
on days 4–7 (or by the time of treatment failure), and who 
did not receive any non-study injectable antibiotic before 
the day 8 visit (unless given because of treatment failure) 
or any non-study oral antibiotic on days 1–3.
We did statistical analyses with Stata version 13. This 
study is registered with ClinicalTrials.gov, number 
NCT01027429.
Role of the funding source
This trial was funded by the Saving Newborn Lives 
initiative of Save the Children, with support from the 
Bill & Melinda Gates Foundation, and by WHO and 
USAID. The funders had a role in study design but played 
no part in data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all the data in the study and was responsible 
for the decision to submit for publication.
Results
Between Jan 1, 2010, and Dec 26, 2013, 41 230 young 
infants were screened for trial eligibility and 2780 (7%) 
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were eligible for enrolment (ﬁ gure). Of these, 63 (2%) 
families agreed to admission and 264 (9%) refused 
participation. Thus, 2453 (88%) of 2780 young infants 
were randomly allocated one of the three study treatments: 
820 were assigned procaine benzylpenicillin and genta-
micin, 816 were allocated amoxicillin and gentamicin, and 
817 were assigned procaine benzyl penicillin, gentamicin, 
and amoxicillin. Table 1 shows baseline characteristics of 
all young infants who were randomly allocated. Median 
age at presentation was 11 days (IQR 2–36). 1083 (44%) 
infants were early neonates (aged 0–6 days), 1309 (53%) 
were boys, and 940 (38%) had a low weight-for-age (Z score 
<–2). 2141 (87%) infants presented with one sign at 
enrolment. Fever was the most common presenting sign 
(1015/2453 [41%]) and was the only presenting sign for 
more than a third of infants (905/2453 [37%]; table 1). 
The next most frequent sign was severe chest indrawing 
(818/2453 [33%]), with around a third having this sign in 
isolation (717/2453 [29%]). 358 (15%) of 2453 infants had 
local infection, of whom 283 (79%) had an umbilical 
infection and 86 (24%) had a skin infection. 1223 (50%) of 
2453 young infants were born in a health facility.
2251 (92%) of 2453 infants who were randomly 
allocated met per-protocol criteria for clinical follow-up 
and treatment adherence (ﬁ gure). 747 received procaine 
benzylpenicillin and gentamicin, 751 were treated with 
amoxicillin and gentamicin, and 753 were given procaine 
benzylpenicillin, gentamicin, and amoxicillin. Per-
protocol infants had similar characteristics at baseline to 
the intention-to-treat population (data not shown). 
Table 2 presents primary and secondary outcome data in 
the per-protocol population. Treatment failure was 
recorded within 7 days of enrolment in 90 (12%) of 
747 infants who received procaine benzylpenicillin and 
gentamicin (reference), 76 (10%) of 751 who were given 
amoxicillin and gentamicin (risk diﬀ erence with 
reference, –1·9, 95% CI –5·1 to 1·3), and 99 (13%) of 
753 treated with procaine benzylpenicillin, gentamicin, 
and amoxicillin (risk diﬀ erence with reference, 1·1, 
–2·3 to 4·5); the upper bound of the 95% CI for both 
comparisons was within the prespeciﬁ ed margin for 
equivalence. The most common causes of treatment 
failure across the three study groups were persistence of 
presenting signs at day 4 (n=62), admission (n=51), and 
clinical deterioration (n=43). In analyses of all randomly 
allocated infants (appendix p 4), treatment failure was 
recorded in 97 (12%) of 820 assigned procaine 
benzylpenicillin and gentamicin (reference), 81 (10%) of 
816 allocated amoxicillin and gentamicin (risk diﬀ erence 
with reference, –1·9, 95% CI –4·9 to 1·1), and 111 (14%) 
of 817 assigned procaine benzylpenicillin, gentamicin, 
and amoxicillin (risk diﬀ erence with reference, 1·8, 
–1·5 to 5·0).
28 (1%) of 2251 infants in the per-protocol analysis died 
within 7 days of enrolment, due to clinical severe illness, 
and the risk of death was similar across the three treat-
ment groups (table 2): 11 (1%) of 747 infants died who 
received procaine benzylpenicillin and gentamicin 
(reference), seven (1%) of 751 died who were treated with 
amoxicillin and gentamicin (risk diﬀ erence with reference 
–0·5, 95% CI –1·6 to 0·6), and ten (1%) of 753 died who 
were given procaine benzylpenicillin, gentamicin, and 
amoxicillin (risk diﬀ erence –0·1, –1·3 to 1·0). No deaths 
were attributable to study procedures. A further 
six children died between day 8 and day 15: two who 
were treated with procaine benzylpenicillin and 
gentamicin (both neonatal sepsis); two who received 
amoxicillin and gentamicin (diarrhoea, and neonatal 
sepsis); and two who were given procaine benzylpenicillin, 
gentamicin, and amoxicillin (neonatal tetanus, and 
neonatal sepsis). None of these six deaths was judged 
attributable to study procedures by the principal 
investigator or the data safety and monitoring board. 
Among all randomly allocated infants, 35 (1%) of 
2453 children had died within 7 days of enrolment 
(appendix p 4), 12 (1%) of 820 children assigned procaine 
Figure: Trial ﬂ ow diagram
*428 children were excluded because of the presence of at least one danger sign of critical illness; 125 had low weight; 
44 had a congenital malformation; 25 needed admission for a surgical reason; 87 had a history of admission in the 
past 2 weeks; 80 had a history of previous enrolment in the study; 55 were out of catchment area; and 106 had other 
comorbid conditions that needed admission. The total excluded is more than 757 because some infants fulﬁ lled more 
than one criterion. †Children were included in the per-protocol analysis if they had complete or adequate clinical 
follow-up and complete or adequate treatment adherence (appendix p 6).
41 230 assessed for eligibility
2780 eligible for enrolment
38 450 not eligible 
 37 693 had a minor or no illness 
 757 excluded*
2453 randomly allocated 
264 refused participation
 63 accepted admission
820 allocated procaine 
 benzylpenicillin and 
 gentamicin
816 allocated amoxicillin and 
 gentamicin
817 allocated procaine 
 benzylpenicillin, gentamicin, 
 and amoxicillin
747 assessed per-protocol†
 73 not included in per-protocol 
  analysis
 51 inadequate clinical 
  follow-up and treatment 
  adherence 
 20 inadequate treatment 
  adherence 
 2 inadequate clinical 
  follow-up 
751 assessed per-protocol†
 65 not included in per-protocol 
  analysis
 40 inadequate clinical 
  follow-up and treatment 
  adherence
 24 inadequate treatment 
  adherence
 1 inadequate clinical 
  follow-up
753 assessed per-protocol†
 64 not included in per-protocol 
  analysis
 35 inadequate clinical 
  follow-up and treatment 
  adherence
 27 inadequate treatment 
  adherence 
 1 inadequate clinical 
  follow-up 
 1 chromosomal 
  abnormality not 
  diagnosed at enrolment
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benzylpenicillin and gentamicin (reference), ten (1%) of 
816 allocated amoxicillin and gentamicin (risk diﬀ erence 
with reference, –0·2, 95% CI –1·4 to 0·9), and 13 (2%) of 
817 assigned procaine benzylpenicillin, gentamicin, and 
amoxicillin (risk diﬀ erence with reference, 0·1,–1·1 to 1·3). 
By day 15, a further three infants had died who were 
allocated procaine benzylpenicillin and gentamicin, 
two children assigned amoxicillin and gentamicin had 
died, and three children died who were allocated procaine 
benzylpenicillin, gentamicin, and amoxicillin.
Three non-fatal serious adverse events were reported 
among the 2453 randomly allocated infants, one in a child 
assigned procaine benzylpenicillin and gentamicin 
(diarrhoea with severe dehydration) and two in children 
allocated amoxicillin and gentamicin (diarrhoea with 
severe dehydration, and generalised rash). Two of these 
three events contributed to the initial reason for treatment 
failure at day 2. All three infants had recovered by the 
day 15 visit and were included in the per-protocol analysis. 
Among the 2251 children in the per-protocol analysis, 
193 (9%) non-serious adverse events occurred, 79 (11%) in 
747 infants treated with procaine benzylpenicillin and 
gentamicin, 55 (7%) in 751 who received amoxicillin and 
gentamicin, and 59 (8%) in 753 who were given procaine 
benzylpenicillin, gentamicin, and amoxicillin. The most 
frequent events were injection-site swelling (n=88) and 
mild diarrhoea (n=81).
Blood cultures were obtained from 2067 (84%) of 
2453 randomly allocated infants, of which 1713 (83%) were 
negative after 5 days of incubation and 273 (13%) were 
contaminated. 81 (4%) cultures were positive for various 
pathogens (appendix p 5); 79 grew a single organism 
whereas two were polymicrobial. Campylobacteraceae 
were the commonest group of pathogens cultured (n=18), 
followed by pseudomonads (n=13), enteric Gram-negative 
bacteria (n=12), and Streptococcus pyogenes (n=8). Of 
23 Gram-positive organisms, 19 (83%) were susceptible to 
penicillin. Of the Gram-negative bacteria, gentamicin 
susceptibility results were available for 14 organisms, 
and all but one Klebsiella pneumoniae isolate were 
gentamicin susceptible. Ampicillin-susceptibility test 
results were available for 18 Gram-negative isolates, and 
nine (50%) were ampicillin susceptible. Overall, 32 (86%) 
of 37 microbes available for antimicrobial susceptibility 
were sensitive to a regimen including penicillin or 
amoxicillin and gentamicin. Ten (13%) of 75 children with 
bacteraemia and 227 (12%) of 1618 without bacteraemia 
had treatment failure; thus, bacteraemia did not predict 
treatment failure in per-protocol infants (risk diﬀ erence 
1·03, 95% CI –6·8 to 8·9). 
Discussion
Our results show that, in Pakistan, simpliﬁ ed antibiotic 
regimens are as eﬃ  cacious as the reference treatment for 
young infants with clinical severe infection whose 
families refuse referral to hospital.2 This ﬁ nding is 
consistent with those of two similar trials from Africa,9 
and Bangladesh.10 Results from these trials have 
contributed to development of new WHO guidelines for 
management of young infants with possible serious 
bacterial infection where referral is not feasible.21
A strength of our Pakistan study is that we included a 
much higher representation of infants aged 0–6 days 
with clinical severe infection (44% of all enrolled 
children) compared with the other randomised 
equivalence trials of the simpliﬁ ed antibiotic regimens 
from Bangladesh10 and Africa (Kenya, Nigeria, and 
Democratic Republic of Congo).9 Additional strengths of 
our study are the availability of bacterial aetiological data 
and antimicrobial susceptibility data. Enrolment of few 
infants younger than 7 days with clinical severe infection 
was judged a limitation of the Bangladesh trial,22 in terms 
of drawing conclusions for this important subgroup at 
high risk of vertically acquired infections and mortality. 
Procaine 
benzylpenicillin and 
gentamicin (n=820)
Amoxicillin and 
gentamicin 
(n=816)
Procaine 
benzylpenicillin, 
gentamicin, and 
amoxicillin (n=817)
Age at enrolment (days)
0–6 361 (44%) 360 (44%) 362 (44%)
7–59 459 (56%) 456 (56%) 455 (56%)
Sex
Male 465 (57%) 419 (51%) 425 (52%)
Female 355 (43%) 397 (49%) 392 (48%)
Weight at enrolment (g)
<2000 62 (8%) 67 (8%) 81 (10%)
2000–2499 145 (18%) 144 (18%) 128 (16%)
≥28 613 (75%) 605 (74%) 608 (74%)
Weight-for-age (Z score)
<–2 303 (37%) 322 (39%) 315 (39%)
≥–2 517 (63%) 494 (61%) 502 (61%)
Number of signs present
One 720 (88%) 717 (88%) 704 (86%)
More than one 100 (12%) 99 (12%) 113 (14%)
Fever 330 (40%) 337 (41%) 348 (43%)
In isolation 296 (36%) 303 (37%) 306 (37%)
Hypothermia 71 (9%) 71 (9%) 91 (11%)
In isolation 43 (5%) 46 (6%) 55 (7%)
Movement only when stimulated 45 (5%) 38 (5%) 39 (5%)
In isolation 10 (1%) 5 (1%) 4 (<1%)
Severe chest indrawing 277 (34%) 272 (33%) 269 (33%)
In isolation 239 (29%) 238 (29%) 240 (29%)
Poor feeding or suck 210 (26%) 205 (25%) 191 (23%)
In isolation 132 (16%) 125 (15%) 99 (12%)
Local infection 122 (15%) 110 (13%) 126 (15%)
Facility delivery* 412 (50%) 388 (48%) 423 (52%)
Maternal age (years)* 25·9 (5·5) 25·8 (5·7) 25·9 (5·5)
Maternal education (years)* 0 (0–4) 0 (0–5) 0 (0–5)
Data are number of children (%), mean (SD), or median (IQR). Signs in isolation were the only clinical sign present at 
enrolment. *Data missing for place of delivery (n=1), maternal age (n=297), and maternal education (n=194).
Table 1: Baseline characteristics 
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A pooled analysis of data from our trial, the Bangladesh 
trial, and the AFRINEST trial in Kenya, Nigeria, and 
Democratic Republic of Congo is underway and will have 
an adequate number of infants aged 0–6 days to support 
policy recommendations for this age group. These 
ﬁ ndings hold great promise in increasing access to 
treatment for sick young infants and improving their 
clinical outcomes.
Data for common bacterial pathogens among young 
infants at the community level are scarce.23 We gathered 
samples for blood culture at the ﬁ rst-level facility, from 
young infants recruited from the community. The 
proportion of infants with clinical sepsis and who grew a 
pathogen from the blood sample was low (4%) but 
comparable with yields reported elsewhere.24,25 Bio markers 
need to be developed to improve our ability to distinguish 
between infants with and without bacterial infection in 
ﬁ rst-level settings.23 Bacteraemia did not predict treatment 
failure in per-protocol infants in our study; however, in 
view of the fairly small number of culture-positive cases, 
we cannot exclude a modest overall increase in risk of 
treatment failure.
Positive blood culture results showed diversity in 
causative agents of clinical severe infection in young 
infants. Campylobacteraceae were the commonest 
pathogens causing bacteraemia and bacteraemic treatment 
failure. Campylobacter jejuni and Campylobacter coli are 
common causes of diarrhoea in infants in developing 
countries, including the area from which these infants 
were recruited;26 however, none of the young infants in this 
study who grew campylobacteraceae from their blood had 
a history of diarrhoea. A related species, Campylobacter 
fetus, has a well known association with adverse birth 
outcomes in cattle.27 It is possible that the fastidious nature 
and special growth requirements of campylobacteraceae 
have resulted in scant recognition of its role as a pathogen 
of newborn bloodstream infections.28
One concern was not borne out—namely, that high 
rates of antimicrobial resistance among newborn 
pathogens reported from hospital-based series from low-
income settings would be a problem for management of 
clinical severe infection in young infants in the 
community. Susceptibility testing showed that a regimen 
based on penicillin or amoxicillin plus gentamicin would 
cover more than 80% of pathogens encountered.
The mix in severity of clinical severe infections in our 
study was aﬀ ected by the proportion of infants identiﬁ ed 
at a very early stage by household surveillance. However, 
we made this trade-oﬀ  to ensure adequate enrolment of 
infants aged 0–6 days who otherwise do not present to 
Procaine 
benzylpenicillin 
and gentamicin 
(n=747)
Amoxicillin 
and 
gentamicin 
(n=751)
Procaine 
benzylpenicillin, 
gentamicin, and 
amoxicillin (n=753)
Risk diﬀ erence† 
(95% CI)
Risk diﬀ erence‡ 
(95% CI)
Primary outcome
Treatment failure within 7 days of enrolment 90 (12%) 76 (10%) 99 (13%) –1·9 (–5·1 to 1·3) 1·1 (–2·3 to 4·5)
Initial reason for treatment failure
Death 6 4 6 ·· ··
Admission 17 13 21 ·· ··
Clinical deterioration 14 12 17 ·· ··
New sign on or after day 3 8 11 3 ·· ··
Persistence of signs at day 4 22 12 28 ·· ··
Recurrence of signs on or after day 5 13 15 16 ·· ··
Persistence of signs at day 8 0 0 0 ·· ··
Serious adverse event 1 1 0 ·· ··
Antibiotic change because of infectious comorbidity 9 8 8 ·· ··
Secondary outcomes
Admission within 7 days of enrolment 26 (3%) 20 (3%) 30 (4%) –0·8 (–2·6 to 0·9) 0·5 (–1·4 to 2·4)
Died within 7 days of enrolment 11 (1%) 7 (1%) 10 (1%) –0·5 (–1·6 to 0·6) –0·1 (–1·3 to 1·0)
Died at any time before day 15 visit 13 (2%) 9 (1%) 12 (2%) –0·5 (–1·8 to 0·7) –0·1 (–1·4 to 1·1)
Not classiﬁ ed as treatment failure with follow-up on 
day 11 or day 15
642 (86%) 661 (88%) 643 (85%) ·· ··
Admission at any time between day 8 and day 15 visits§ 6 (1%) 2 (<1%) 1 (<1%) ·· ··
Died any time between day 8 and day 15 visits§ 0 1 (<1%) 2 (<1%) ·· ··
Non-fatal relapse at any time between day 8 and 
day 15 visits§
20 (3%) 9 (1%) 6 (1%) –1·8 (–3·4 to –0·1) –2·2 (–3·7 to –0·6)
Data are number of children (%), unless otherwise stated. *Secondary outcomes for all randomly allocated infants are presented in the appendix (p 4). †Diﬀ erence between 
amoxicillin and gentamicin, and procaine benzylpenicillin and gentamicin. ‡Diﬀ erence between procaine benzylpenicillin, gentamicin, and amoxicillin, and procaine 
benzylpenicillin and gentamicin. §Denominator was children not classiﬁ ed as treatment failures with follow-up to day 11 or day 15.
Table 2: Primary and secondary treatment outcomes (per-protocol population)* 
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facilities. Another consideration is whether the milder 
spectrum of illness, potentially including many children 
without a bacterial infection, could have biased the results 
of our trial towards equivalence. Although some enrolled 
children will undoubtedly not have had a bacterial 
infection, in a pilot study3 using the same inclusion 
criteria as this study, a signiﬁ cantly higher rate of 
treatment failure was reported among children treated 
with co-trimoxazole and gentamicin compared with those 
treated with procaine benzylpenicillin and gentamicin.
Our study shares some limitations with the trials in 
Africa and Bangladesh.22,23 First, we did not mask clinicians 
or participants for ethical reasons;22 placebo injections 
were not judged justiﬁ able in sick young infants. Second, 
families of enrolled infants most probably refused 
admission because their child was not perceived to be very 
sick.22,23 Critical illness was a chosen exclusion criterion in 
the design phase because we believed treatment of very 
sick young infants with simpliﬁ ed antibiotic regimens 
would have been unethical. Nevertheless, 35 (1%) of 
2453 trial participants died despite antimicrobial treatment 
and 265 (12%) of 2251 per-protocol infants did not respond 
to treatment, indicating a substantial level of severe illness 
among enrolled children. Third, concern has been raised 
about observer bias in assessing the soft study endpoints.23 
Quality of clinical assessment was ensured through repeat 
training and supervision, and all treatment failures were 
conﬁ rmed independently by another study clinician, as 
described elsewhere.8,29 Fourth, most infants were 
diagnosed clinically without availability of laboratory tests 
to indicate the presence or absence of infection. Since the 
main aim of this study was to ﬁ nd pragmatic solutions to 
scant access to antibiotic treatment for most young infants 
with newborn infections in low-resource settings, in 
environments where laboratory testing will not be 
available in the near future, we chose to use clinical 
deﬁ nitions. Nevertheless, it is noteworthy that because of 
the absence of reliable laboratory tests to diagnose 
newborn infections, and the high risk of adverse 
outcomes, it is common practice to diagnose neonatal 
sepsis clinically and treat empirically with antibiotics 
pending laboratory results, even in high-resource hospital 
settings. Finally, although low case-fatality was recorded 
with the study treatments under stringent trial conditions 
and close monitoring, application of these ﬁ ndings in 
programmatic settings might not yield such impressive 
results when adherence with treatment might be lower. 
The programmatic eﬀ ect of implementation of these 
guidelines must be assessed carefully.
Our data show that simpliﬁ ed antibiotic regimens with 
fewer injections administered closer to home by a trained 
health provider were as eﬃ  cacious as a reference strategy 
comprising more penicillin-gentamicin injections for 
treatment of young infants with clinical severe infection 
whose families declined admission. Overall, this evidence 
supports easier to administer regimens and can inform 
national and international policy on the treatment of sick 
young infants in situations when hospital admission is 
not accepted.
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